flow trial semaglutide kidney outcomes nejm 2024 hazard ratio significant 24% reduction in disease progression and death related to kidney and cardiovascular causes in those treated with compared to a placebo FLOW clinical Trial (funded by

Description

We also go beyond the research, interviewing top experts in their fields to bring you the most informed insights

Is compounded semaglutide approved by the FDA

Fella focuses on overall metabolic health, which means hormonal balance as well as weight loss

We designed our programs to fit into any busy lifestyle at a price you can afford

While cost and supply remain major challenges, clinicians expect the next wave of medications to push policymakers toward expanding access, especially as global medical bodies like the American Medical Association (AMA) call obesity a chronic disease deserving of insurance coverage